<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02181049</url>
  </required_header>
  <id_info>
    <org_study_id>CVSS-study</org_study_id>
    <nct_id>NCT02181049</nct_id>
  </id_info>
  <brief_title>Cardiac and Vascular Late Sequelae in Long-term Survivors of Childhood Cancer (CVSS)</brief_title>
  <acronym>CVSS</acronym>
  <official_title>Cardiac and Vascular Late Sequelae in Long-term Survivors of Childhood Cancer (CVSS): a Multidisciplinary Clinical, Epidemiological and Genetic Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CVSS study</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Univ. Prof. Dr. med. Joerg Faber, Center for Pediatrics, Hematology, Oncology and Hemostaseology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Univ. Prof. Dr. med. Philipp S. Wild, MSc, Preventive Cardiology and Preventive Medicine, Center for Cardiology, Clinical Epidemiology, CTH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. oec. troph. Hiltrud Merzenich, Insitute for Medical Biometry, Epidemiology and Informatics (IMBEI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Due to remarkable advances in childhood cancer therapy the 10-year survival rate increased to&#xD;
      over 80% and late sequelae come to the fore. Childhood cancer survivors (CCS) suffer from&#xD;
      significant excess in mortality risk associated with treatment-related complications at least&#xD;
      for 25 years after the initial cancer diagnosis. In particular, the prevalence of&#xD;
      cardiovascular disease seems to be elevated compared to the general population. The CVSS&#xD;
      study is a multi-disciplinary cooperation project between the Institute for Medical&#xD;
      Biostatistics, Epidemiology and Informatics (IMBEI) and the German Childhood Cancer Registry&#xD;
      (GCCR), the Preventive Cardiology and Preventive Medicine and the Pediatric Hematology and&#xD;
      Oncology all at the University Medical Center of the Johannes Gutenberg University Mainz. The&#xD;
      central element is a thorough clinical cardiovascular examination of all patients, which&#xD;
      permits detecting subclinical disease. Therapy data will be extracted retrospectively from&#xD;
      various sources. The study intends to describe the current situation of a cohort of&#xD;
      approximately 1000 CCS in Germany aged 24 to 49 years with respect to cardiovascular health.&#xD;
      The role of risk factors (treatment related and classic cardiovascular risk factors), as well&#xD;
      as related predisposing genetic factors is investigated. The results will contribute to&#xD;
      recommendations to improve follow-up care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Anticipated">October 2028</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Heart failure</measure>
    <time_frame>up to 35 years after exposure to childhood cancer therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypertension</measure>
    <time_frame>up to 35 years after exposure to childhood cancer therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>up to 35 years after exposure to childhood cancer therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late-occurring stroke</measure>
    <time_frame>up to 35 years after exposure to childhood cancer therapy</time_frame>
    <description>&quot;late&quot; is defined as 5 years or more after diagnosis of cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid artery disease</measure>
    <time_frame>up to 35 years after exposure to childhood cancer therapy</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">1000</enrollment>
  <condition>Childhood and Adolescence Cancer (Survivors and Deceased)</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, serum, plasma, DNA, RNA, urine, tear fluid&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Survivors of a oncological disease according to ICCC-3 aged &lt;15 years at diagnosis,&#xD;
        diagnosed 1980-1990 while resident in Germany&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Survivors of oncological disease according to ICCC-3 aged &lt;15 years at diagnosis,&#xD;
             diagnosed 1980-1990 while resident in Germany&#xD;
&#xD;
          2. Declaration of consent for storage of personal data at GCCR&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has refused contact with GCCR&#xD;
&#xD;
          2. Current address not available&#xD;
&#xD;
          3. Second malignant neoplasm&#xD;
&#xD;
          4. Diagnosis Morbus Hodgkin&#xD;
&#xD;
          5. Diagnosis WILMS tumor in 1990&#xD;
&#xD;
          6. Former treating center recommends exclusion&#xD;
&#xD;
          7. Insufficient knowledge of German language&#xD;
&#xD;
          8. Inability to travel to the study center and participate in the examinations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Joerg Faber, Univ.-Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Pediatrics, Pediatric Hematology, Oncology and Hemostaseology, University Medical Center of the Johannes Gutenberg University Mainz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philipp S Wild, Univ.-Prof. Dr. med. MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Preventive Cardiology and Preventive Medicine, Center for Cardiology, Clinical Epidemiology, Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University Mainz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hiltrud Merzenich, Dr. oec. troph.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center of the Johannes Gutenberg University Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rhineland-Palatinate</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 27, 2014</study_first_submitted>
  <study_first_submitted_qc>July 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2014</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>CVSS study</investigator_full_name>
    <investigator_title>interdisciplinary cooperation</investigator_title>
  </responsible_party>
  <keyword>Childhood cancer survivors</keyword>
  <keyword>Cardiac</keyword>
  <keyword>Vascular</keyword>
  <keyword>Cardiovascular</keyword>
  <keyword>Late-sequelae</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Death</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

